New hormone treatment shows promise for rare adrenal condition
NCT ID NCT05299554
First seen Feb 04, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study looked at the long-term safety of a drug called Chronocort for people aged 16 and older with congenital adrenal hyperplasia (CAH), a condition where the body can't make enough cortisol. Over 76 participants were monitored for signs of over- or under-treatment, adrenal crises, and side effects. The goal was to see if Chronocort is safe to use over time to help manage this lifelong condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Center
Bethesda, Maryland, 20892-1932, United States
-
Neurocrine Investigational Site in Asahi-ku
Yokohama, Kanagawa, 241-0811, Japan
-
Neurocrine Investigational Site in Caen
Caen, 14033, France
-
Neurocrine Investigational Site in California
Los Angeles, California, 90027, United States
-
Neurocrine Investigational Site in California
Orange, California, 92868, United States
-
Neurocrine Investigational Site in Florida
Jacksonville, Florida, 32207, United States
-
Neurocrine Investigational Site in Iowa
Iowa City, Iowa, 52242, United States
-
Neurocrine Investigational Site in Michigan
Ann Arbor, Michigan, 48114, United States
-
Neurocrine Investigational Site in Minnesota
Rochester, Minnesota, 55901, United States
-
Neurocrine Investigational Site in Nevada
Las Vegas, Nevada, 89148, United States
-
Neurocrine Investigational Site in Okura
Setagaya-Ku, Tokyo, 157-8535, Japan
-
Neurocrine Investigational Site in Paris
Paris, 75651, France
-
Neurocrine Investigational Site in Pessac
Pessac, 33604, France
-
Neurocrine Investigational Site in Texas
Dallas, Texas, 75235, United States
-
Neurocrine Investigational Site in Toulouse
Toulouse, 31059, France
-
Neurocrine Investigational Site in Toulouse (Children's hospital)
Toulouse, 31059, France
-
Neurocrine Investigational Site in Toyama
Shinjuku-Ku, Tokyo, 162-8655, Japan
-
Neurocrine Investigational Site in Washington
Seattle, Washington, 98105, United States
-
Neurocrine Investigational Site in Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Neurocrine Investigational Site in Yushima
Bunkyō-Ku, Tokyo, 113-8519, Japan
-
Neurocrine investigational Site in Lyon
Lyon, 69677, France
Conditions
Explore the condition pages connected to this study.